Paving the Road to Tumor Development and Spreading: Myeloid-Derived Suppressor Cells are Ruling the Fate
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Cancer development is dependent on intrinsic cellular changes as well as inflammatory factors in the tumor macro and microenvironment. The inflammatory milieu nourishes the tumor and contributes to cancer progression. Numerous studies, including ours, have demonstrated that the tumor microenvironment is immunosuppressive, impairing the anticancer immune responses. Chronic inflammation was identified as the key process responsible for this immunosuppression via induction of immature myeloid-derived suppressor cells (MDSCs). Upon a prolonged immune response, MDSCs are polarized toward immunosuppressive cells meant to control the exacerbated immune response. In cancer, the chronic inflammatory response renders the MDSCs harmful. Polarized MDSCs suppress T-cells and natural killer cells, as well as antigen-presenting cells, abrogating the beneficial immune response. These changes in the immunological milieu could also lead to high frequency of mutations, enhanced cancer cell stemness, and angiogenesis, directly supporting tumor initiation, growth, and spreading. The presence of MDSCs in cancer poses a serious obstacle in a variety of immune-based therapies, which rely on the stimulation of antitumor immune responses. Cumulative data, including our own, suggest that the selection of an appropriate and effective anticancer therapy must take into consideration the host's immune status as well as tumor-related parameters. Merging biomarkers for immune monitoring into the traditional patient's categorization and follow-up can provide new predictive and diagnostic tools to the clinical practice. Chronic inflammation and MDSCs could serve as novel targets for therapeutic interventions, which can be combined with conventional cancer treatments such as chemotherapy, radiotherapy, and cancer cell-targeted and immune-based therapies. Intervention in environmental and tumor-specific inflammatory mechanisms will allow better clinical management of cancer toward more efficient treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic inflammation and cytokines in the tumor microenvironment
Landskron, G., De la Fuente, M., Thuwajit, P., Thuwajit, C., & Hermoso, M. A. (2014) · Journal of Immunology Research · doi:10.1155/2014/149185 · Cited by 1,765 · cited 1×
“Tumor-associated macrophages (TAM), tumor-infiltrating lymphocytes (TIL), and cancer-associated fibroblasts (CAF) secrete several factors that contribute to tumor growth and metastasis while maintaining the immunosuppressive milieu (63) (Figure 1D).”
BackgroundMacrophages, innate immunity and cancer: balance, tolerance, and diversity
Mantovani, A., & Sica, A. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.01.009 · Cited by 1,484
Huang, B., Pan, P.-Y., Li, Q., Sato, A. I., Levy, D. E., Bromberg, J., Divino, C. M., & Chen, S.-H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1299 · Cited by 1,435 · cited 8×
“However, it is well established that under pathological conditions, increasing accumulation of growth factors [GM-CSF and VEGF (16)], chemokines [CXCL12 (17) and CCL2 (16)], and cytokines [TNF-α, IFN-γ, IL-1β, IL-6, and TGF-β (18)] accelerate MDSC expansion in the BM and accumulation in the periphery.”
BackgroundInfluentialYang, L., DeBusk, L. M., Fukuda, K., Fingleton, B., Green-Jarvis, B., Shyr, Y., Matrisian, L. M., Carbone, D. P., & Lin, P. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.031 · Cited by 1,140 · cited 1×
“MMP9 produced by MDSCs has been suggested to augment VEGF production and enhance tumor vasculature, growth, and invasiveness in mouse models (57, 58).”
BackgroundL-arginine availability regulates T-lymphocyte cell-cycle progression.
Rodriguez, P. C., Quiceno, D. G., & Ochoa, A. C. (2007) · Blood · doi:10.1182/blood-2006-06-031856 · Cited by 926
Aggarwal, B. B., Gupta, S. C., & Kim, J. H. (2012) · Blood · doi:10.1182/blood-2011-04-325225 · Cited by 877 · cited 1×
“TNF-α is generated by a variety of immune and non-immune cells such as T-cells, NK cells, macrophages and tumor cells, endothelial cells, mast cells, neurons, and fibroblasts (24).”
BackgroundMeyer, C., Cagnon, L., Costa-Nunes, C. M., Baumgaertner, P., Montandon, N., Leyvraz, L., Michielin, O., Romano, E., & Speiser, D. E. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1508-5 · Cited by 560
Bell, D., Chomarat, P., Broyles, D., Netto, G., Harb, G. M., Lebecque, S., Valladeau, J., Davoust, J., Palucka, K. A., & Banchereau, J. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.10.1417 · Cited by 544 · cited 2×
“Prevention of Dendritic Cell Maturation Accumulating data show that tumor residing DCs can retain an immature phenotype and induce tolerance to tumor antigens (41, 42).”
BackgroundKrelin, Y., Voronov, E., Dotan, S., Elkabets, M., Reich, E., Fogel, M., Huszar, M., Iwakura, Y., Segal, S., Dinarello, C. A., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2956 · Cited by 285
Immunosuppressive CD14+HLA-DRlow/− monocytes in B-cell non-Hodgkin lymphoma
Lin, Y., Gustafson, M. P., Bulur, P. A., Gastineau, D. A., Witzig, T. E., & Dietz, A. B. (2011) · Blood · doi:10.1182/blood-2010-05-283820 · Cited by 244
Cited by
Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
Weber, R., Fleming, V., Hu, X., Nagibin, V., Groth, C., Altevogt, P., Utikal, J., & Umansky, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01310 · Cited by 538
Mira, J. C., Gentile, L. F., Mathias, B. J., Efron, P. A., Brakenridge, S. C., Mohr, A. M., Moore, F. A., & Moldawer, L. L. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002074 · Cited by 526
“It is well accepted that cancer patients who are cachectic (73), are immunosuppressed (74), and have chronic inflammation (75) have lower life expectancies than those who do not.”
BackgroundMyeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer
Law, A. M. K., Valdes-Mora, F., & Gallego-Ortega, D. (2020) · Cells · doi:10.3390/cells9030561 · Cited by 455
Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression
Fleming, V., Hu, X., Weber, R., Nagibin, V., Groth, C., Altevogt, P., Utikal, J., & Umansky, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00398 · Cited by 443
The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression
Umansky, V., Blattner, C., Gebhardt, C., & Utikal, J. (2016) · Vaccines · doi:10.3390/vaccines4040036 · Cited by 438
Mathias, B., Delmas, A. L., Ozrazgat-Baslanti, T., Vanzant, E. L., Szpila, B. E., Mohr, A. M., Moore, F. A., Brakenridge, S. C., Brumback, B. A., Moldawer, L. L., et al. (2017) · Annals of Surgery · doi:10.1097/sla.0000000000001783 · Cited by 279
Horiguchi, H., Loftus, T. J., Hawkins, R. B., Raymond, S. L., Stortz, J. A., Hollen, M. K., Weiss, B. P., Miller, E. S., Bihorac, A., Larson, S. D., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00595 · Cited by 164
Autoimmunity and Inflammation in Myelodysplastic Syndromes
Wolach, O., & Stone, R. (2016) · Acta Haematologica · doi:10.1159/000446062 · Cited by 51
Metadata
- Authors
- Meirow, Y., Kanterman, J., & Baniyash, M.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2015-10-12
- Volume
- 6
- Pages
- 523-523
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2158885476
- Cited by
- 89
- References
- 10
- FWCI
- 4.81
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.